<p>北极星资产管理公司在最近向证券交易委员会的披露中表示，在第四季度将其在雅培（NYSE:ABT - 免费报告）的持股比例提高了 4.0%。该机构投资者在本季度增持了 12,271 股后，持有 316,783 股这家医疗产品制造商的股票。雅培约占北极星资产管理公司持股的 1.6%，使其成为该公司第 11 大持股。北极星资产管理公司在雅培的持股在最近的报告期末价值为 39,690,000 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>AbbVie 发出健康趋势跟随信号：反弹即将到来吗？</li>
</ul>
<p>其他对冲基金最近也增加或减少了对该公司的持股。Harbor Capital Advisors Inc.在第四季度新购入了价值约 27,000 美元的雅培股份。Cloud Capital Management LLC 在第三季度新购入了价值约 29,000 美元的雅培股份。Guerra Advisors Inc 在第三季度新购入了价值约 31,000 美元的雅培股份。Bridge Generations Wealth Management LLC 在第三季度新购入了价值约 33,000 美元的雅培股份。最后，Copia Wealth Management 在第三季度新购入了价值约 38,000 美元的雅培股份。机构投资者和对冲基金持有该公司 75.18% 的股票。</p>
<h2>雅培股票表现</h2>
<p>雅培股票在周五开盘价为 87.42 美元。该公司的 50 日简单移动平均线为 96.74 美元，200 日简单移动平均线为 112.05 美元。该股票的市值为 1522.7 亿美元，市盈率为 24.49，PEG 比率为 1.46，贝塔值为 0.65。雅培的 12 个月低点为 81.97 美元，12 个月高点为 139.06 美元。该公司的债务与股本比率为 0.56，流动比率为 1.39，速动比率为 1.01。</p>
<ul>
<li>雅培股票崩盘：反弹可能即将到来</li>
</ul>
<p>雅培（NYSE:ABT - 获取免费报告）最近在 4 月 16 日（星期四）公布了其财报。该医疗产品制造商报告本季度每股收益为 1.15 美元，超出分析师一致预期的 1.14 美元，超出幅度为 0.01 美元。该季度的营业收入为 111.6 亿美元，而分析师预期为 109.9 亿美元。雅培的净利润率为 13.90%，股本回报率为 17.62%。该公司的季度收入同比增长 7.8%。在去年同期，该公司每股收益为 1.09 美元。雅培已将其 2026 财年的指导目标设定为每股收益 5.380-5.580 美元，2026 年第二季度的指导目标设定为每股收益 1.250-1.310 美元。整体来看，股票分析师预测雅培在当前年度的每股收益将达到 5.48 美元。</p>
<h2>分析师评级升级与降级</h2>
<p>多位分析师对该股票发表了看法。大和证券集团将雅培的股票评级从 “跑赢大盘” 下调至 “中性”，并设定了 92.00 美元的目标价。在 4 月 22 日（星期三）的报告中，富国银行将雅培的股票目标价从 122.00 美元下调至 109.00 美元，并给予 “增持” 评级。在 4 月 17 日（星期五）的报告中，花旗集团将雅培的股票目标价从 136.00 美元下调至 108.00 美元，并给予 “买入” 评级。Argus 在 4 月 21 日（星期二）的报告中将雅培的股票目标价从 140.00 美元下调至 125.00 美元，并给予 “买入” 评级。最后，派珀·桑德勒在 4 月 17 日（星期五）的报告中将雅培的股票目标价从 135.00 美元下调至 115.00 美元，并给予 “增持” 评级。有两位研究分析师对该股票给予 “强烈买入” 评级，十九位分析师给予 “买入” 评级，五位分析师给予 “持有” 评级。根据 MarketBeat 的数据，雅培的共识评级为 “适度买入”，共识目标价为 119.43 美元。</p>
<ul>
<li>一家股息王正在打折出售：雅培是否是医疗保健的便宜货？</li>
</ul>
<p><strong>查看我们最新的雅培股票报告</strong></p>
<h2>更多雅培新闻</h2>
<p>以下是本周影响雅培的主要新闻：</p>
<ul>
<li>积极情绪：TipRanks 的汇总显示，雅培是三只 “强烈买入” 股息贵族股票之一，具有超过 15% 的上涨潜力，这可能会增强投资者对该公司的信心。3 只 ‘强烈买入’ 股息贵族股票，15%+ 上涨潜力，2026 年 5 月 22 日</li>
<li>积极情绪：另一篇文章认为，雅培的 Lingo 可穿戴设备和增加的心血管研发可能通过扩大其健康科技和诊断领域来增强其长期增长前景。雅培的 Lingo 可穿戴设备和心血管研发重塑长期增长故事</li>
<li>中性情绪：一份市场报告称，交易者在等待整合结果的更多明确性，暗示投资者处于 “展示我” 的阶段，而不是完全重新定价该股票。等待整合结果，市场对雅培（ABT）保持温和</li>
<li>消极情绪：另一篇文章称，雅培的股价部分下滑是因为其营养部门对消费者支出趋势敏感，突显了对关键业务线的宏观压力。雅培（ABT）因其营养部门对消费者支出动向的敏感性而下滑</li>
<li>消极情绪：高盛据报道将雅培从其美国信念名单中移除，这可能会对情绪产生影响，尽管这并未改变公司的基本面。尽管政策和成本压力，为什么联合健康（UNH）仍然是一个翻身的赌注</li>
</ul>
<h2>内部人士下注</h2>
<p>在其他新闻中，执行副总裁 Daniel Gesua Sive Salvadori 于 3 月 2 日星期一出售了 885 股雅培（Abbott Laboratories）股票，交易的平均价格为 115.58 美元，总价值为 102,288.30 美元。交易后，这位执行副总裁直接持有公司 146,377 股股票，价值为 16,918,253.66 美元。此次交易使其持股减少了 0.60%。该出售在向 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，董事 Daniel J. Starks 于 4 月 27 日星期一购买了 10,000 股公司的股票，股票的平均购买成本为每股 92.65 美元，总交易额为 926,500.00 美元。完成购买后，该董事直接持有公司 6,751,103 股股票，价值为 625,489,692.95 美元。此次交易使其持股增加了 0.15%。该购买的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士出售了 3,055 股公司股票，价值为 353,097 美元。公司内部人士持有 0.46% 的公司股票。</p>
<h2>雅培公司简介</h2>
<p>（免费报告）</p>
<p>雅培（Abbott Laboratories）是一家全球医疗保健公司，总部位于伊利诺伊州的雅培公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
<p>在诊断领域，雅培提供实验室和现场检测平台及检测方法，用于检测传染病、慢性病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>Workday 验证 AI 飞轮：股票价格恢复开始</li>
<li>HubSpot 在 2019 年水平是一个机会——而不是警告</li>
<li>Decker 的双重超预期是看涨信号——还是仅仅是 HOKA 的把戏？</li>
<li>Kiniksa Pharmaceuticals 在 100% 反弹后仍有上涨空间</li>
</ul>
<p><strong>想看看其他对 ABT 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培并不在名单上。</p>
<p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

标普健康医疗设备 ETF - SPDR

基因改革 ETF - ARK

标普全球医疗股指数 ETF - iShares

医疗业 ETF - Vanguard

医疗业 ETF - SPDR

美国制药 ETF - iShares

美国医药设备 ETF - iShares

<p>北星资产管理公司在第四季度将其在雅培（NYSE:ABT）的持股增加了 4.0%，目前持有 316,783 股，市值为 3969 万美元。该公司现在是北星的第 11 大持股。其他对冲基金也增持了雅培的股份。该股票开盘价为 87.42 美元，市值为 1522.7 亿美元。分析师的评级意见不一，普遍评级为 “适度买入”，目标价为 119.43 美元</p>

<p>North Star Asset Management Inc. boosted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 316,783 shares of the healthcare product maker's stock after acquiring an additional 12,271 shares during the quarter. Abbott Laboratories accounts for about 1.6% of North Star Asset Management Inc.'s holdings, making the stock its 11th biggest holding. North Star Asset Management Inc.'s holdings in Abbott Laboratories were worth $39,690,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>北极星资产管理公司在最近向证券交易委员会的披露中表示，在第四季度将其在雅培（NYSE:ABT - 免费报告）的持股比例提高了 4.0%。该机构投资者在本季度增持了 12,271 股后，持有 316,783 股这家医疗产品制造商的股票。雅培约占北极星资产管理公司持股的 1.6%，使其成为该公司第 11 大持股。北极星资产管理公司在雅培的持股在最近的报告期末价值为 39,690,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 发出健康趋势跟随信号：反弹即将到来吗？</li>
</ul>
</div><p>Other hedge funds have also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $27,000. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories during the third quarter worth approximately $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories during the third quarter worth approximately $31,000. Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories during the third quarter worth approximately $33,000. Finally, Copia Wealth Management acquired a new stake in Abbott Laboratories during the third quarter worth approximately $38,000. Institutional investors and hedge funds own 75.18% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金最近也增加或减少了对该公司的持股。Harbor Capital Advisors Inc.在第四季度新购入了价值约 27,000 美元的雅培股份。Cloud Capital Management LLC 在第三季度新购入了价值约 29,000 美元的雅培股份。Guerra Advisors Inc 在第三季度新购入了价值约 31,000 美元的雅培股份。Bridge Generations Wealth Management LLC 在第三季度新购入了价值约 33,000 美元的雅培股份。最后，Copia Wealth Management 在第三季度新购入了价值约 38,000 美元的雅培股份。机构投资者和对冲基金持有该公司 75.18% 的股票。</p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表现</h2>
</div><p>Shares of Abbott Laboratories stock opened at $87.42 on Friday. The firm's fifty day simple moving average is $96.74 and its 200-day simple moving average is $112.05. The stock has a market capitalization of $152.27 billion, a price-to-earnings ratio of 24.49, a PEG ratio of 1.46 and a beta of 0.65. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.</p>
<div class="lb-trans"><p>雅培股票在周五开盘价为 87.42 美元。该公司的 50 日简单移动平均线为 96.74 美元，200 日简单移动平均线为 112.05 美元。该股票的市值为 1522.7 亿美元，市盈率为 24.49，PEG 比率为 1.46，贝塔值为 0.65。雅培的 12 个月低点为 81.97 美元，12 个月高点为 139.06 美元。该公司的债务与股本比率为 0.56，流动比率为 1.39，速动比率为 1.01。</p>
</div><ul>
<li>Abbott Stock Crash: Rebound Could Be Coming Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培股票崩盘：反弹可能即将到来</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analysts' expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company's quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近在 4 月 16 日（星期四）公布了其财报。该医疗产品制造商报告本季度每股收益为 1.15 美元，超出分析师一致预期的 1.14 美元，超出幅度为 0.01 美元。该季度的营业收入为 111.6 亿美元，而分析师预期为 109.9 亿美元。雅培的净利润率为 13.90%，股本回报率为 17.62%。该公司的季度收入同比增长 7.8%。在去年同期，该公司每股收益为 1.09 美元。雅培已将其 2026 财年的指导目标设定为每股收益 5.380-5.580 美元，2026 年第二季度的指导目标设定为每股收益 1.250-1.310 美元。整体来看，股票分析师预测雅培在当前年度的每股收益将达到 5.48 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>A number of analysts have weighed in on the stock. Daiwa Securities Group cut shares of Abbott Laboratories from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $92.00 price objective on the stock. in a report on Wednesday, April 22nd. Wells Fargo &amp; Company cut their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, April 17th. Citigroup cut their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, April 17th. Argus cut their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday, April 21st. Finally, Piper Sandler cut their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $119.43.</p>
<div class="lb-trans"><p>多位分析师对该股票发表了看法。大和证券集团将雅培的股票评级从 “跑赢大盘” 下调至 “中性”，并设定了 92.00 美元的目标价。在 4 月 22 日（星期三）的报告中，富国银行将雅培的股票目标价从 122.00 美元下调至 109.00 美元，并给予 “增持” 评级。在 4 月 17 日（星期五）的报告中，花旗集团将雅培的股票目标价从 136.00 美元下调至 108.00 美元，并给予 “买入” 评级。Argus 在 4 月 21 日（星期二）的报告中将雅培的股票目标价从 140.00 美元下调至 125.00 美元，并给予 “买入” 评级。最后，派珀·桑德勒在 4 月 17 日（星期五）的报告中将雅培的股票目标价从 135.00 美元下调至 115.00 美元，并给予 “增持” 评级。有两位研究分析师对该股票给予 “强烈买入” 评级，十九位分析师给予 “买入” 评级，五位分析师给予 “持有” 评级。根据 MarketBeat 的数据，雅培的共识评级为 “适度买入”，共识目标价为 119.43 美元。</p>
</div><ul>
<li>A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?</li>
</ul>
<div class="lb-trans"><ul>
<li>一家股息王正在打折出售：雅培是否是医疗保健的便宜货？</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on ABT</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的雅培股票报告</strong></p>
</div><h2>More Abbott Laboratories News</h2>
<div class="lb-trans"><h2>更多雅培新闻</h2>
</div><p>Here are the key news stories impacting Abbott Laboratories this week:</p>
<div class="lb-trans"><p>以下是本周影响雅培的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: A TipRanks roundup highlighted Abbott as one of three “Strong Buy” dividend aristocrat stocks with more than 15% upside potential, which may support investor confidence in the name. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26</li>
<li>Positive Sentiment: Another piece argued that Abbott’s Lingo wearable and increased cardiovascular R&amp;D could strengthen its long-term growth outlook by expanding its health-tech and diagnostics footprint. Abbott’s Lingo Wearable And Cardio R&amp;D Reframe Long Term Growth Story</li>
<li>Neutral Sentiment: One market note said traders are waiting for more clarity on integration results, suggesting investors are in a “show-me” phase rather than fully repricing the stock higher. Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT)</li>
<li>Negative Sentiment: Another article said Abbott has been “slid” in part because its nutrition segment is sensitive to consumer spending trends, highlighting macro pressure on a key business line. Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum</li>
<li>Negative Sentiment: Goldman Sachs reportedly removed Abbott from its U.S. Conviction List, which may weigh on sentiment even though it does not change the company’s fundamentals. Why UnitedHealth (UNH) Remains a Turnaround Bet Despite Policy and Cost Pressure</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：TipRanks 的汇总显示，雅培是三只 “强烈买入” 股息贵族股票之一，具有超过 15% 的上涨潜力，这可能会增强投资者对该公司的信心。3 只 ‘强烈买入’ 股息贵族股票，15%+ 上涨潜力，2026 年 5 月 22 日</li>
<li>积极情绪：另一篇文章认为，雅培的 Lingo 可穿戴设备和增加的心血管研发可能通过扩大其健康科技和诊断领域来增强其长期增长前景。雅培的 Lingo 可穿戴设备和心血管研发重塑长期增长故事</li>
<li>中性情绪：一份市场报告称，交易者在等待整合结果的更多明确性，暗示投资者处于 “展示我” 的阶段，而不是完全重新定价该股票。等待整合结果，市场对雅培（ABT）保持温和</li>
<li>消极情绪：另一篇文章称，雅培的股价部分下滑是因为其营养部门对消费者支出趋势敏感，突显了对关键业务线的宏观压力。雅培（ABT）因其营养部门对消费者支出动向的敏感性而下滑</li>
<li>消极情绪：高盛据报道将雅培从其美国信念名单中移除，这可能会对情绪产生影响，尽管这并未改变公司的基本面。尽管政策和成本压力，为什么联合健康（UNH）仍然是一个翻身的赌注</li>
</ul>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares of the company's stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Daniel J. Starks acquired 10,000 shares of the company's stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders sold 3,055 shares of company stock worth $353,097. Corporate insiders own 0.46% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Daniel Gesua Sive Salvadori 于 3 月 2 日星期一出售了 885 股雅培（Abbott Laboratories）股票，交易的平均价格为 115.58 美元，总价值为 102,288.30 美元。交易后，这位执行副总裁直接持有公司 146,377 股股票，价值为 16,918,253.66 美元。此次交易使其持股减少了 0.60%。该出售在向 SEC 的法律文件中披露，相关信息可通过此链接获取。此外，董事 Daniel J. Starks 于 4 月 27 日星期一购买了 10,000 股公司的股票，股票的平均购买成本为每股 92.65 美元，总交易额为 926,500.00 美元。完成购买后，该董事直接持有公司 6,751,103 股股票，价值为 625,489,692.95 美元。此次交易使其持股增加了 0.15%。该购买的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士出售了 3,055 股公司股票，价值为 353,097 美元。公司内部人士持有 0.46% 的公司股票。</p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培（Abbott Laboratories）是一家全球医疗保健公司，总部位于伊利诺伊州的雅培公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在诊断领域，雅培提供实验室和现场检测平台及检测方法，用于检测传染病、慢性病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>Workday Validates AI Flywheel: Stock Price Recovery Begins</li>
<li>HubSpot at 2019 Levels Is an Opportunity—Not a Warning</li>
<li>Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?</li>
<li>Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>Workday 验证 AI 飞轮：股票价格恢复开始</li>
<li>HubSpot 在 2019 年水平是一个机会——而不是警告</li>
<li>Decker 的双重超预期是看涨信号——还是仅仅是 HOKA 的把戏？</li>
<li>Kiniksa Pharmaceuticals 在 100% 反弹后仍有上涨空间</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ABT 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Abbott Laboratories $ABT Shares Purchased by North Star Asset Management Inc.

Market Beat

艾伯维

Daiwa Securities Group Inc.

富国银行

花旗

Piper Sandler Cos

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

CITIGROUP INC 6.250 NON CUM SER II PFD WI

北极星资产管理公司购买了雅培公司 $ABT 的股票